Clinical Trials | November 14, 2025
Roche reports breakthrough phase III results for investigational multiple sclerosis drug
Fenebrutinib targets cells in the immune system known as B cells and microglia
Fenebrutinib targets cells in the immune system known as B cells and microglia
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
Relmada expects to initiate its Phase 3 program in the first half of 2026
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Subscribe To Our Newsletter & Stay Updated
